Mechanisms of Antiaddictive Actions of Ibogaine a

  title={Mechanisms of Antiaddictive Actions of Ibogaine a},
  author={Stanley D. Glick and Isabelle M. Maisonneuve},
  journal={Annals of the New York Academy of Sciences},
ABSTRACT: Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long‐acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. Studies in this laboratory have used animal models to characterize ibogaine's interactions with drugs of abuse, and to investigate the mechanisms responsible. Ibogaine, as well as its metabolite, noribogaine, can decrease both morphine and cocaine self‐administration for several days in some rats; shorter… 

Ibogaine and Noribogaine: Comparing Parent Compound to Metabolite

Attempts to correlate brain levels of both, the parent compound and the metabolite indicate that noribogaine is primarily responsible for ibogaine discriminative stimulus, and Ibogaine-induced neurotoxicity tends to occur at doses much higher than the proposed dose for humans.

Application of Electrophysiological Method to Study Interactions between Ibogaine and Cocaine

The alterations in ECoG and neurotransmitter levels suggest a decreased response to COC following IBO pretreatment, seen concomitantly with increased or decreased motor activity after subsequent amphetamine or cocaine administration.

Iboga interactions with psychomotor stimulants: panacea in the paradox?

Noribogaine (12‐Hydroxyibogamine): A Biologically Active Metabolite of the Antiaddictive Drug Ibogaine

The present data demonstrate that NORIBO is biologically active and undoubtedly contributes to the in vivo pharmacological profile of IBO in rats, and appears less likely to produce the adverse effects associated with IBO (i.e., tremors and stress‐axis activation), suggesting that the metabolite may be a safer alternative for medication development.

Noribogaine, but not 18‐MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self‐administration

Whether noribogaine and/or 18‐MC, like ibogaine, increase GDNF expression, and whether their site of action to reduce alcohol consumption is the VTA is determined, which suggests that noribogsaine and 18-MC have different mechanisms and sites of action.

18‐Methoxycoronaridine (18‐MC) and Ibogaine: Comparison of Antiaddictive Efficacy, Toxicity, and Mechanisms of Action

The data suggest that 18‐MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine, and is likely to have an active metabolite.

In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.

The present findings demonstrate that noribogaine is biologically active and undoubtedly contributes to the in vivo pharmacological profile of ibogaine in rats and appears less apt to produce the adverse effects associated with ibogain, indicating the metabolite may be a safer alternative for medication development.

Long-Lasting Ibogaine Protection against NMDA-Induced Convulsions in Mice

Ibogaine (80 mg/kg, ip) was effective in inhibiting convulsions induced by NMDA at 24 and 72 hours post administration, and [3H] MK-801 binding was significantly decreased at24 and 72 h post ibogaine, suggesting that this long lasting and complex pattern of modulation of NMDA receptors prompted by a single dose of Ibogaine may be associated to its antiaddictive properties.



NMDA antagonist properties of the putative antiaddictive drug, ibogaine.

Findings link the NMDA antagonist actions of ibogaine to a putative "antiaddictive" property of this alkaloid, its ability to reduce the expression of morphine dependence.